Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00308581 · ClinicalTrials.gov registry record · Phase 3
Certolizumab in Crohn's Disease Patients With Loss of Response or Intolerance to Infliximab
A Phase 3 study, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 539
- Enrollment target
NCT00308581 is a Phase 3 study that has completed, run by UCB Pharma. The registered enrollment target is 539 participants.
The verdict
NCT00308581, a Phase 3 study, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 539 participants
- Enrollment target
Study Summary
To assess the clinical efficacy of subcutaneous (sc) certolizumab pegol administration over 26 weeks in patients suffering from Crohn's Disease (CD) and previously treated with infliximab
Interventions
- OTHER Placebo
- BIOLOGICAL Certolizumab pegol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 539 participants |
| Start Date | 2006-04 |
| Est. Completion | 2008-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00308581
The ClinicalTrials.gov registry entry for NCT00308581 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 539 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Pharma, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00308581 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00308581 about?
NCT00308581 is a clinical study titled "Certolizumab in Crohn's Disease Patients With Loss of Response or Intolerance to Infliximab". To assess the clinical efficacy of subcutaneous (sc) certolizumab pegol administration over 26 weeks in patients suffering from Crohn's Disease (CD) and previously treated with infliximab
What is the current status of trial NCT00308581?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 539 participants. The study started on 2006-04. Estimated completion is 2008-04.
What interventions are being tested in trial NCT00308581?
The interventions under investigation include: Placebo (OTHER), Certolizumab pegol (BIOLOGICAL).
Who is sponsoring clinical trial NCT00308581?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.